Barroso-Sousa Romualdo, Metzger-Filho Otto
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Yawkey 1238, Boston, MA 02215, USA.
Ther Adv Med Oncol. 2016 Jul;8(4):261-6. doi: 10.1177/1758834016644156. Epub 2016 Apr 25.
Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer (BC): ILC differs from invasive ductal carcinoma (IDC) in its clinicopathological characteristics and responsiveness to systemic therapy. From the clinical standpoint, data suggest that ILC derives a distinct benefit from systemic therapy compared to IDC. In addition, comprehensive molecular analyses have been reported for ILCs, confirming that these tumors have specific genomic profiles compared to IDC. Despite these differences, clinical trials and practical clinical guidelines tend to treat BC as a single entity. Here we discuss these clinical and molecular data and their therapeutic implications.
浸润性小叶癌(ILC)是乳腺癌(BC)的第二大常见组织学亚型:ILC在临床病理特征和对全身治疗的反应方面与浸润性导管癌(IDC)不同。从临床角度来看,数据表明与IDC相比,ILC从全身治疗中获得了明显的益处。此外,已有关于ILC的综合分子分析报道,证实这些肿瘤与IDC相比具有特定的基因组特征。尽管存在这些差异,但临床试验和实际临床指南倾向于将乳腺癌视为一个单一实体。在此我们讨论这些临床和分子数据及其治疗意义。